Why the study?
Fibrin degradation products are considered a crucial marker for cross-linked fibrin turnover and hemostatic system activation in cardiovascular diseases, prompting evaluation of their levels in Sudanese ACS patients.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Omer et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: